Incidence and prevalence of gout in Western Sweden
Incidence and prevalence of gout in Western Sweden
复制标题
DOI：
10.1186/s13075-016-1062-6
复制
发表时间：
2016-07-13
影响因子：
4.9
通讯作者：
Jacobsson, Lennart T. H.
中科院分区：
文献类型：
--
作者：
Dehlin, Mats;Drivelegka, Panagiota;Jacobsson, Lennart T. H.
背景：本研究的目的是描述2002年至2012年瑞典西部医疗保健地区痛风的患病率和发病率趋势，以及降低尿酸治疗(ULT)的模式。方法：我们使用地区和国家医疗登记来估计2012年痛风的患病率和发病率，以及2005年至2012年每个日历年的发病率趋势。结果：2012年，在20岁及以上人群中，痛风的患病率为1.8%(95%可信区间为1.77~1.82)，发病率为190例(95%可信区间为180~200)/10万人年。对痛风病例采用更严格的定义，其患病率分别为每10万人年1.36%(95%可信区间1.34至1.38)和0.5(95%可信区间0.49至0.51)。从2005年到2012年，痛风的发病率稳步显著上升，总人口增加了近50%。与城市地区相比，农村地区痛风的患病率没有显著差异。2012年只有42%的痛风患者在过去10年中被诊断为痛风。结论：痛风是瑞典WSHCR最常见的关节炎疾病，在过去10年中大幅增加，2012年只有少数流行病例使用ULT。
Background: The aim of the present study was to describe prevalence and trends in the incidence of gout and patterns of urate-lowering treatment (ULT) in the Western Swedish Health Care Region (WSHCR) from 2002 to 2012.Methods: We used regional and national healthcare registers to estimate the prevalence and incidence of gout in 2012, and trends in incidence for each calendar year from 2005 to 2012. We also investigated the pattern of ULT for gout using the Swedish Prescribed Drug Register.Results: In 2012, in the population aged 20 years and above, the prevalence of gout was 1.8 % (95 % confidence interval (CI) 1.77 to 1.82) and the incidence was 190 cases (95 % CI 180 to 200) per 100,000 person-years. Applying more strict definitions for a gout case rendered a prevalence of 1.36 % (95 % CI 1.34 to 1.38) and 0.5 (95 % CI 0.49 to 0.51) per 100,000 person-years, respectively. The incidence of gout increased steadily and significantly from 2005 to 2012, with an almost 50 % increase in the total population. There was no significant difference in the prevalence of gout in rural compared to urban areas. ULT was dispensed to only 42 % of patients with gout in 2012 who had ever been diagnosed with gout during the preceding 10-year period.Conclusions: Gout is the most common arthritic disease in WSHCR, Sweden, and has increased substantially over the last decade, with only a minority of prevalent cases in 2012 receiving ULT.